Abbott Laboratories (ABT) EBT (2009 - 2026)

Abbott Laboratories' EBT history runs 18 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• In Q1 2026, EBT fell 18.5% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $8.1 billion (up 10.63% YoY), while the FY2025 annual figure was $8.5 billion, up 20.72% from the prior year.
• EBT came in at $1.4 billion for Q1 2026 at Abbott Laboratories, down from $2.4 billion in the prior quarter.
• In the past five years, EBT ranged from a high of $2.9 billion in Q1 2022 to a low of $1.3 billion in Q4 2022.
• A 5-year average of $1.9 billion and a median of $1.8 billion in 2025 frame the typical range for EBT.
• Across the five-year window, EBT jumped 74.48% in 2022 and slumped 45.69% in 2023, its largest moves.
• Abbott Laboratories' EBT stood at $1.3 billion in 2022, then surged by 35.98% to $1.8 billion in 2023, then grew by 13.09% to $2.0 billion in 2024, then climbed by 16.16% to $2.4 billion in 2025, then tumbled by 38.55% to $1.4 billion in 2026.
• According to Business Quant data, EBT over the past three periods registered $1.4 billion, $2.4 billion, and $2.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison